Rubicon says FY earnings beat guidance as ArborGen moves out of R&D phase

Rubicon says FY earnings beat guidance as ArborGen moves out of R&D phase
Rebecca Howard
By Rebecca Howard May 28 (BusinessDesk) -  NZX-listed forestry investor Rubicon says it beat its target of doubling annual earnings as its ArborGen unit shifts into full commercialisation, posting a muddle of numbers including a new balance date and pared back business units.  Auckland-based Rubicon aligned its balance date with its fully-owned subsidiary ArborGen, which sells and develops advanced genetic seedlings to improve forest productivity and is its only asset, to Sept. 30 from June 30 and today released first-half accounts. The f...